Heart Disease & Cardiology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

This Phase 4 study is looking at how the drug mavacamten affects the heart structure in adults with symptomatic obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal is to see if mavacamten can improve heart function and reduce symptoms, potentially offering a new treatment option for patients living with this condition. The study is currently active in multiple countries with 63 participants involved.

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

This Phase 3 trial tested Baxdrostat, an oral medication, in adults whose high blood pressure remains uncontrolled despite taking multiple medications. The results, now available, may help determine if Baxdrostat can better manage blood pressure and lower the risk of heart-related problems for people with resistant hypertension. More than 200 participants from various countries took part in this study.

A Trial of CRD-4730 in HFrEF

This Phase 2 trial is evaluating CRD-4730, a new oral drug, for patients with heart failure with reduced ejection fraction, a type of heart failure where the heart does not pump blood efficiently. If successful, CRD-4730 could be added to current treatments to improve heart function and ease symptoms. The study is recruiting participants in the United States with a planned treatment period of 24 weeks.

Rapid or Ultra-rapid Diagnosis of Myocardial Infarction Using High-Sensitivity Cardiac Troponin on Hospital Presentation

This study is testing two different timing approaches for a blood test used to diagnose heart attacks in adults who arrive at the hospital with chest pain. The aim is to find out if testing after just 1 hour is as safe as the current 3-hour wait, which could lead to faster diagnosis and shorter hospital stays. Recruitment is ongoing across Denmark with a large number of participants.

Mobile Health Intervention to Increase Activity in Heart Failure Study

This study explores whether a mobile health program can help patients with heart failure become more physically active. The program uses notifications and coaching to encourage healthier habits, which may help patients feel better and improve their quality of life. The trial is recruiting in the United States and aims to enroll 50 participants.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.